Clinical trials: Fatty Liver Disease
Non-alcoholic Steatohepatitis
Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants
This is a single-center, randomized, double-blind, placebo-controlled Phase I clinical study, divided into two parts. The first part is a single-dose escalation study (Part1,SAD study phase), and the second part is a…
- Trial name
- NCT06716905
- Testing
- ACT500 tablets
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Hepatic Impairment, Healthy Volunteers
Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma PK of PF-06865571.
- Trial name
- NCT04091061
- Testing
- PF-06865571 100 mg
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
NASH
A Multicenter, Double-blind, Placebo-randomized Controlled Clinical Study on the Treatment of Non-alcoholic Steatohepatitis With Tibetan Drug Langqing Atar
non-alcoholic steatohepatitis (NASH) is an inflammatory liver disease caused by the accumulation of fat in liver cells. With the change of living habits and diet, the incidence of Nash continues to increase.
- Trial name
- NCT06193629
- Testing
- Lang Qingata
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Shupei Li
Insulin Resistance, Type2 Diabetes Mellitus
High-fat Overfeeding, Hepatokines and Appetite Regulation
The present study will investigate the effect of high-fat overfeeding on a group of liver-secreted proteins linked to worsened blood sugar control, as well as proteins involved in appetite control.
- Conditions
- Insulin Resistance, Type2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, Obesity
- Trial name
- OVEREAT (NCT03369145)
- Testing
- High-fat diet
- Where
- 2 sites in United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Loughborough University
Liver Diseases, Primary Biliary Cirrhosis
Repeatability and Reproducibility of Multiparametric MRI
This study aims to prospectively assess the repeatability and reproducibility of iron-corrected T1 (cT1), T2*, and hepatic proton density fat fraction (PDFF) quantification with multiparametric MRI using the LiverMultiScan™ (LMS…
- Conditions
- Liver Diseases, Primary Biliary Cirrhosis, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
- Trial name
- NCT03743272
- Testing
- LiverMultiScan
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Perspectum
Diabetes Mellitus, Type 1, NASH
Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes
Background: Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD) that can precipitate to advanced fibrosis and leads to cardiovascular morbidity and mortality.
- Trial name
- NCT06348706
- Testing
- Dipeptidyl peptidase 4 (DPP-4) inhibitor
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
MASLD, HIV (Human Immunodeficiency Virus)
Lipidomic and Multi-Omics Profiling of Fatty Liver Disease in People With and Without HIV
Metabolic dysfunction-associated steatotic liver disease (MASLD), commonly known as fatty liver disease, is increasingly prevalent worldwide.
- Trial name
- MASLD (NCT07640880)
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Yinzhong Shen
Metabolic Disorders, Non-alcoholic Steatohepatitis
A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects
This Phase 1, first-in-human (FiH), single-ascending-dose (SAD) study, will assess the safety and tolerability and characterize the pharmacokinetics (PK) of AZD2693, following subcutaneous (SC) SAD administration of AZD2693 in…
- Trial name
- NCT04142424
- Testing
- AZD2693
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
NAFLD
Resolution of Liver Fat in Non-alcoholic Fatty Liver Disease
The major adverse health consequences of obesity occur only when non-alcoholic fatty liver disease (NAFLD) also develops. NAFLD is characterized by abnormal hepatic accumulation of triglycerides and other lipids.
- Trial name
- NCT02558530
- Testing
- Low carbohydrate diet
- Where
- 2 sites in Finland, Sweden
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
The purpose of this study is to directly characterize the pharmacokinetic (PK) profiles of MGL-3196 and its major metabolite (MGL-3623) following administration of multiple oral doses (QD x 6 days) in subjects with varying…
- Conditions
- Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
- Trial name
- NCT04643795
- Testing
- MGL-3196
- Where
- 3 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Healthy
A Phase 1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers. Primary Objectives: 1.
- Trial name
- NCT00776841
- Testing
- Aramchol
- Where
- Israel
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Galmed Medical Reserch
Fatty Liver Disease
Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
To investigate the prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among adults in China
- Trial name
- MAFLD (NCT05421572)
- Testing
- Fibrotouch
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease
Liver Stiffness And Steatosis Assessment In Women With Polycystic Ovary Syndrome Using Fibroscan
Polycystic Ovary Syndrome (PCOS) is a complex endocrine and metabolic disorder prevalent among women of reproductive age. It is closely associated with insulin resistance, obesity, and metabolic dysfunction, often leading to…
- Trial name
- NCT07027332
- Testing
- FibroScan® (Echosens, Paris, France)
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bezmialem Vakif University
Cardiovascular Diseases, Osteoporosis
Guangzhou Nutrition and Health Study (GNHS)
Purpose: The Guangzhou Nutrition and Health Study (GNHS) project aims to assess the determinants of metabolic disease in nutritional aspects, as well as other environmental and genetic factors, and explore possible mechanisms…
- Conditions
- Cardiovascular Diseases, Osteoporosis, Diabetes Mellitus, Type 2, Metabolic Syndrome
- Trial name
- GNHS (NCT03179657)
- Volunteers
- 5,118 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
NAFLD, Type 2 Diabetes
Study Visceral Adipose Tissue and Liver Stifness in a Retrospective Cohort of Diabetes Mellitus Patients
Non Alcoholic Fatty Liver Disease (NAFLD) is an emergent disease worldwide, and soon the leading cause of hepatic transplant in the USA.
- Trial name
- NCT04493814
- Where
- France
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Type2 Diabetes, NAFLD
Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins
High-protein diets have been recently demonstrated to effectively reduce insulin resistance, derangements of the lipid profile and liver fat content in subjects with moderately and severely impaired glucose metabolism and…
- Trial name
- MOCA (NCT04564391)
- Testing
- protein supplement
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
NAFLD, Obesity
Intermittent Fasting, Mediterranean Diet and NAFLD
This study aims to evaluate the effects of Intermittent Fasting (IF) 14/10 compared with the Low Glycemic Index Mediterranean Diet on NAFLD.
- Conditions
- NAFLD, Obesity, Intermittent Fasting, Mediterranean Diet
- Trial name
- RC2024-21 (NCT06615817)
- Testing
- Intermittent Fasting
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Non-Alcoholic Fatty Liver Disease
Fatty Liver Disease in Nordic Countries
A prospective cohort study, which aims to systematically evaluate biomarkers and potential targets in NAFLD and NASH.
- Trial name
- FLINC (NCT04340817)
- Testing
- Proteomics, Transcriptomics, Genomics
- Where
- Denmark
- Volunteers
- 634 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Hvidovre
Hepatic Cirrhosis, Liver Fibrosis
A Study of Experimental Medication BMS-986036 Given to Healthy Participants
This is a study of experimental medication BMS-986036 given to healthy participants.
- Conditions
- Hepatic Cirrhosis, Liver Fibrosis, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
- Trial name
- NCT03445208
- Testing
- BMS-986036
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Simultaneous Quantification of Liver Fat Content, Fatty Acid Composition, and Fibrosis Using Spin-lock MRI for Steatohepatitis Assessment
Non-alcoholic fatty liver disease is a major health problem worldwide. It includes simple steatosis and NASH which has inflammation in the liver, with or without fibrosis.
- Trial name
- NCT05384652
- Where
- Hong Kong
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong